Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06788639 · ClinicalTrials.gov registry record
A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
A clinical trial of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.
- Recruiting
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT06788639: Recruiting study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.
NCT06788639 is a study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) that is actively recruiting participants, run by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. The registered enrollment target is 300 participants, above the 181-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (66% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06788639, a study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), is actively recruiting participants, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to characterize the long-term safety of lisocabtagene maraleucel (liso-cel), focusing on patients treated in the chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities
Conditions Studied
Interventions
- BIOLOGICAL Lisocabtagene maraleucel
Study Locations (1)
Wisconsin
- Center for International Blood and Marrow Transplant Research (CIBMTR) - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-02-04 |
| Est. Completion | 2044-06-30 |
What NCT06788639 shows while recruiting
NCT06788639 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 181-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (66% higher).
The record links to 2 conditions, with Chronic Lymphocytic Leukemia (CLL) appearing as the primary indexed condition, and to 1 intervention - of which Lisocabtagene maraleucel is the first listed.
NCT06788639 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06788639 about?
NCT06788639 is a clinical study titled "A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting". The purpose of this study is to characterize the long-term safety of lisocabtagene maraleucel (liso-cel), focusing on patients treated in the chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities
What is the current status of trial NCT06788639?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2025-02-04. Estimated completion is 2044-06-30.
What conditions does trial NCT06788639 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL).
What interventions are being tested in trial NCT06788639?
The interventions under investigation include: Lisocabtagene maraleucel (BIOLOGICAL).
Who is sponsoring clinical trial NCT06788639?
This trial is sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06788639 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia (CLL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06788639's enrollment target sits among peer trials
300 4th of 29 higher than 26 of 29 other Chronic Lymphocytic Leukemia (CLL) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia (CLL) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
RECRUITING · Phase 2
-
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
RECRUITING · Phase 2
-
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI